Evidence map›Paper›PMID 41070602›Full record

ReviewMolecular medicine reports2025

Zi-Tong Qin, Zhi-Hang Wu, Can-Mo Wang, Xiu-Chen Xie, Ying-Hao Wang

Abstract readReview
In one paragraph

Review in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. International journal of molecular sciences · 2026
    Article
  2. Review
  3. The role ofFrontiers in immunology · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zi-Tong Qin *College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350000, P.R. China.
Zhi-Hang Wu *The Department of General Surgery, Union Hospital Affiliated to Fujian Medical University, Fuzhou, Fujian 350000, P.R. China.
Can-Mo WangCollege of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350000, P.R. China.
Xiu-Chen XieCollege of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350000, P.R. China.
Ying-Hao WangCollege of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The management of malignant neoplasms has consistently posed a challenge within the global medical community. Due to the efficacy demonstrated by various immunomodulatory agents in the therapeutic intervention of tumorigenic diseases, immunotherapeutic strategies have emerged as a promising option for the treatment of cancer. Among these,

Indexed as

Antineoplastic AgentsAntineoplastic Agents, PhytogenicAstragalus PlantImmunologic FactorsImmunomodulating AgentsNeoplasmsPolysaccharidesAnimalsAstragalus propinquusHumansImmunomodulationTumor MicroenvironmentAntineoplastic AgentsAntineoplastic Agents, PhytogenicImmunologic FactorsImmunomodulating AgentsPolysaccharidesAstragalus polysaccharidemultidrug resistancetumor immunotherapytumor microenvironment

Identifiers

PMID41070602
PMCPMC12522034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.